Onkológia 3/2017

Mantle cell lymhoma and modern therapy – benefit for the patient

Purpose: The objective is to present a case report of a patient with Mantle cell lymphoma (MCL) and show, how can a complex treatment with modern drugs has possitive influence on overall survival (OS), in the daily life of standard quality , also for patients with advanced disease and multiple treatment lines. Case: Despite several relapses and failures of indicated treatment, and at the time when all patient ´s physical reserves seemed exhausted, after many years since the onset od diagnosis, she achieved a remission and benefits from the treatment with modern drugs, lives her optimal quality life. Patient´s overall survival from diagnosis is more then nine years so far. Conclusion: Mantle cell lymphoma is one of the clinically aggressive form of non-Hodgkin‘s lymphomas (NHL). Although in the past three decades, thanks to the innovative treatment the overall survival (OS) in MCL has doubled, the median of overall survival is only 4-5 years at present. Tumor responds well to first-line treatment, standardly immunochmotherapy, then there is a relapse soon, as well as resistance to further treatment, often with very poor prognosis for the patient. Except for rare cases of patients who have long-term disease-free survival after non-myeloablative allogeneic stem cell transplantation, there is no effective treatment for the relaps of this aggressive form of malignant disease.

Keywords: mantle cell lymphoma, complex modern tratment